Search results for " infarction"

showing 10 items of 1141 documents

Valor pronóstico de la troponina T en pacientes hospitalizados con angina o infarto sin elevación del segmento ST

2003

Introduction and objectives. Cardiac troponins are highly specific and sensitive for detecting minimal myocardial damage. The aim of our study was to determine the prognostic value of troponinT levels in patients hospitalized for suspected angina or myocardial infarction without STsegment elevation. Patients and method. We recorded the frequency of death, acute myocardial infarction, heart failure, or need for coronary revascularization in the three months after the onset of symptoms in 346 consecutive patients admitted for suspected acute coronary syndrome, excluding those who developed myocardial infarction with persistent ST-segment elevation. Results. Serum troponin T levels were ≥ 0.1 …

Acute coronary syndromemedicine.medical_specialtyTroponin TUnstable anginabusiness.industrymedicine.diseaseChest painAnginaInternal medicineHeart failuremedicineCardiologyMyocardial infarction diagnosisMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

2021

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required i…

Acute coronary syndromemedicine.medical_specialtyacute coronary syndrome; cardiogenic shock; glycoprotein IIb/IIIa receptor inhibitors; myocardial infarction; percutaneous coronary interventionmedicine.medical_treatmentArticleacute coronary syndromeInternal medicineAngioplastyRisk of mortalityMedicineMyocardial infarctionAdverse effectbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseaseglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionConventional PCICardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

0436: Diagnostic value of serial ultrasensible troponin I measurements for acute coronary syndrome identification in cardiac intensive care unit

2014

Introduction ACS diagnosis relies on the detection of an increase or a decrease in troponin levels (delta-TnI) that might be estimated as absolute (delta-TnI-abs) or relative value (delta-TnI-rel). The discriminative cut-off value of delta-TnI to identify ACS in patients admitted in ICU is a matter of debate. Methods We aimed to determine in a monocentric registry the cut-off value of delta-TnI to identify ACS among patients admitted in ICU with a suspicion of acute myocardial ischemia. All the patients had 2 measurements of ultrasensible cTnI (ADVIA Centaur Siemens®; 99th percentile: 0,04 μg/L). Patients were classified in 4 groups: 1) ACS (NSTEMI, UA), 2) Cardiac non coronary diseases (he…

Acute coronary syndromemedicine.medical_specialtybiologybusiness.industrymedicine.diseaseChest painmusculoskeletal systemTroponinPericarditisInternal medicineHeart failureTroponin ImedicineCoronary care unitbiology.proteinCardiologycardiovascular systemMyocardial infarctionmedicine.symptombusinessCardiology and Cardiovascular MedicineArchives of Cardiovascular Diseases Supplements
researchProduct

Post-Infectious Myocardial Infarction: New Insights for Improved Screening

2019

Acute infection is suspected of involvement in the onset of acute myocardial infarction (MI). We aimed to assess the incidence, pathogenesis and prognosis of post-infectious MI. All consecutive patients hospitalized for an acute MI in coronary care units were prospectively included. Post-infectious MI was defined by a concurrent diagnosis of acute infection at admission. Type 1 MI (acute plaque disruption) or Type 2 MI (imbalance in oxygen supply/demand) were adjudicated according to the universal definition of MI. From the 4573 patients admitted for acute MI, 466 (10%) had a concurrent acute infection (median age 78 (66–85) y, 60% male), of whom 313 (67%) had a respiratory tract infection.…

Acute coronary syndromemedicine.medical_specialtylcsh:Medicine030204 cardiovascular system & hematologyType 2 myocardial infarctionelderlyArticleacute coronary syndromeSepsisPathogenesissepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicinepneumonia030212 general & internal medicineMyocardial infarctionbusiness.industryIncidence (epidemiology)lcsh:Rpulmonary tract infectionGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalinfectionPneumoniabusinessin-hospital mortalityJournal of Clinical Medicine
researchProduct

Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER…

2021

Abstract Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk–benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. Methods and results The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarct…

Acute limb ischaemiamedicine.medical_specialtyBrain IschemiaPeripheral Arterial DiseaseRivaroxabanInternal medicineClinical endpointHumansMedicineMyocardial infarctionAgedRivaroxabanAspirinbusiness.industryAbsolute risk reductionNumber needed to harmmedicine.diseaseStrokeCardiologyNumber needed to treatDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsTIMIFactor Xa Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Cystatin C levels are decreased in acute myocardial infarction: Effect of cystatin C G73A gene polymorphism on plasma levels

2005

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

Acute myocardial infarctionCystatin CCoronary artery diseaseUnstable angina
researchProduct

Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocard…

2007

N-terminal pro-b-type natriuretic peptide (NT pro-BNP) is a neurohormone synthesized predominantly in ventricular myocardium. In patients with symptoms of heart failure, elevation in NT pro-BNP accurately identifies ventricular dysfunction. However, NT pro-BNP levels are not specific for ventricular dysfunction in patients who do not have overt symptoms of heart failure, suggesting that other cardiac processes such as myocardial ischemia may also cause elevation in NT pro-BNP. The study was aimed to determine whether NT pro-BNP elevations are associated with myocardial ischemia.One hundred and thirty patients (104 males, 26 females, mean age 61+12 years), with ST elevation acute myocardial …

AdultAged 80 and overMaleTomography Emission-Computed Single-PhotonMyocardial InfarctionMyocardial IschemiaOrganotechnetium CompoundsMiddle AgedSensitivity and SpecificityPeptide FragmentsElectrocardiographyLogistic ModelsOrganophosphorus CompoundsROC CurvePredictive Value of TestsNatriuretic Peptide BrainExercise TestOdds RatioHumansFemaleRadiopharmaceuticalsBiomarkersAgedEchocardiography StressRetrospective Studies
researchProduct

Comprehensive coordinated care after myocardial infarction (KOS-Zawał) : a patient's perspective

2019

AdultAged 80 and overmedicine.medical_specialtybusiness.industryPerspective (graphical)Myocardial InfarctionMiddle Agedmedicine.diseaseSurveys and QuestionnairesmedicineHumansComprehensive Health CarePolandMyocardial infarctionCardiology and Cardiovascular MedicineIntensive care medicinebusinessAged
researchProduct

TLR2 and age-related diseases: potential effects of Arg753Gln and Arg677Trp polymorphisms in acute myocardial infarction.

2008

ABSTRACT Inflammation is a key component of immune system. It is involved in both defense and pathophysiological events maintaining the dynamic homeostasis of host organism. Its function is controlled by innate immunity genes. Both their polymorphisms and environmental conditions give rise to different phenotypes in human population. Proinflammatory genotype may be beneficial in early life but not in old people. With advancing age, indeed, it increases the vulnerability and the intensity to inflammatory reactions responsible for the chronic inflammatory diseases, such as atherosclerosis and myocardial infarction (MI). Several studies have looked for detecting a genetic risk profile that mig…

AdultAgingSettore MED/09 - Medicina InternaGenotypePopulationMyocardial InfarctionInflammationPolymorphism Single NucleotideProinflammatory cytokineImmune systemGene FrequencyMedicineHumansMyocardial infarctioneducationSettore MED/04 - Patologia Generaleeducation.field_of_studyInnate immune systembusiness.industryMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareToll-Like Receptor 2TLR2Amino Acid SubstitutionItalyTLR2age-related diseasespolymorphismsacute myocardial infarction.PharmacogenomicsCase-Control StudiesImmunologyGeriatrics and Gerontologymedicine.symptombusinessRejuvenation research
researchProduct

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

2023

The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics,…

AdultAngiotensin Receptor AntagonistsAspirinHealth PolicyHumansAngiotensin-Converting Enzyme InhibitorsHospital MortalityRegistries03.02. Klinikai orvostanNon-ST Elevated Myocardial InfarctionCardiology and Cardiovascular Medicine
researchProduct